These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 21342381)

  • 21. 18-fluorodeoxyglucose positron emission tomography in the early diagnostic workup of differentiated thyroid cancer patients with a negative post-therapeutic iodine scan and detectable thyroglobulin.
    van Dijk D; Plukker JT; Phan HT; Muller Kobold AC; van der Horst-Schrivers AN; Jansen L; Sluiter WJ; Brouwers AH; Links TP
    Thyroid; 2013 Aug; 23(8):1003-9. PubMed ID: 23517405
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Initial experience in use of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography in thyroid carcinoma patients with elevated serum thyroglobulin but negative iodine-131 whole body scans.
    Ong SC; Ng DC; Sundram FX
    Singapore Med J; 2005 Jun; 46(6):297-301. PubMed ID: 15902358
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnostic value of recombinant human thyrotropin-stimulated ¹²³I whole-body scintigraphy in the follow-up of patients with differentiated thyroid cancer.
    Alzahrani AS; AlShaikh O; Tuli M; Al-Sugair A; Alamawi R; Al-Rasheed MM
    Clin Nucl Med; 2012 Mar; 37(3):229-34. PubMed ID: 22310247
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels.
    Wang W; Macapinlac H; Larson SM; Yeh SD; Akhurst T; Finn RD; Rosai J; Robbins RJ
    J Clin Endocrinol Metab; 1999 Jul; 84(7):2291-302. PubMed ID: 10404792
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Can (18)F-FDG-PET/CT be generally recommended in patients with differentiated thyroid carcinoma and elevated thyroglobulin levels but negative I-131 whole body scan?
    Bannas P; Derlin T; Groth M; Apostolova I; Adam G; Mester J; Klutmann S
    Ann Nucl Med; 2012 Jan; 26(1):77-85. PubMed ID: 22006540
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of positron emission tomography/computed tomography in the management of recurrent papillary thyroid carcinoma.
    Nahas Z; Goldenberg D; Fakhry C; Ewertz M; Zeiger M; Ladenson PW; Wahl R; Tufano RP
    Laryngoscope; 2005 Feb; 115(2):237-43. PubMed ID: 15689742
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnostic accuracy of serial CT/magnetic resonance imaging review vs. positron emission tomography/CT in colorectal cancer patients with suspected and known recurrence.
    Potter KC; Husband JE; Houghton SL; Thomas K; Brown G
    Dis Colon Rectum; 2009 Feb; 52(2):253-9. PubMed ID: 19279420
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of 18F-Fluorodeoxyglucose Positron Emission Tomography in patients with suspected recurrence or metastatic differentiated thyroid carcinoma with elevated serum thyroglobulin and negative I-131 whole body scan.
    Trybek T; Kowalska A; Lesiak J; Młynarczyk J
    Nucl Med Rev Cent East Eur; 2014; 17(2):87-93. PubMed ID: 25088108
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic value of FDG PET/CT imaging.
    Pace L; Nicolai E; Klain M; Salvatore M
    Q J Nucl Med Mol Imaging; 2009 Oct; 53(5):503-12. PubMed ID: 19910903
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Breast metastasis by medullary thyroid carcinoma detected by FDG positron emission tomography.
    Nofech-Mozes S; Mackenzie R; Kahn HJ; Ehrlich L; Raphael SJ
    Ann Diagn Pathol; 2008 Feb; 12(1):67-71. PubMed ID: 18164420
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer.
    Feine U; Lietzenmayer R; Hanke JP; Held J; Wöhrle H; Müller-Schauenburg W
    J Nucl Med; 1996 Sep; 37(9):1468-72. PubMed ID: 8790195
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Positron emission tomography-computed tomography evaluation for recurrent differentiated thyroid carcinoma.
    Makeieff M; Burcia V; Raingeard I; Eberlé MC; Cartier C; Garrel R; Crampette L; Guerrier B
    Eur Ann Otorhinolaryngol Head Neck Dis; 2012 Oct; 129(5):251-6. PubMed ID: 22818209
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer.
    de Groot JW; Links TP; Jager PL; Kahraman T; Plukker JT
    Ann Surg Oncol; 2004 Aug; 11(8):786-94. PubMed ID: 15289241
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic factors affecting disease-specific survival in patients with recurrent and/or metastatic differentiated thyroid carcinoma detected by positron emission tomography/computed tomography.
    Akkas BE; Demirel BB; Vural GU
    Thyroid; 2014 Feb; 24(2):287-95. PubMed ID: 23750862
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FDG PET and alternative imaging in the management of thyroid carcinoma.
    Al-Nahhas AM
    Nucl Med Rev Cent East Eur; 2003; 6(2):139-45. PubMed ID: 14737730
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Patients treated for differentiated thyroid cancer with negative 131I whole-body scans and elevated thyroglobulin levels: a possible course].
    Gutiérrez Cardo AL; Rodríguez Rodríguez JR; Borrego Dorado I; Navarro González E; Tirado Hospital JL; Vázquez Albertino R
    Rev Esp Med Nucl; 2007; 26(3):138-45. PubMed ID: 17524307
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical usefulness of FDG PET in differentiated thyroid cancer.
    Macapinlac HA
    J Nucl Med; 2001 Jan; 42(1):77-8. PubMed ID: 11197984
    [No Abstract]   [Full Text] [Related]  

  • 38. How has the management of medullary thyroid carcinoma changed with the advent of 18F-FDG and non-18F-FDG PET radiopharmaceuticals.
    Wong KK; Laird AM; Moubayed A; Chondrogiannis S; Marzola MC; Evangelista L; Gross MD; Rubello D
    Nucl Med Commun; 2012 Jul; 33(7):679-88. PubMed ID: 22422100
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Investigation of thyroid, head, and neck cancers with PET.
    Zhuang H; Kumar R; Mandel S; Alavi A
    Radiol Clin North Am; 2004 Nov; 42(6):1101-11, viii. PubMed ID: 15488560
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Utility of positron emission tomography in sarcomas.
    Schuetze SM
    Curr Opin Oncol; 2006 Jul; 18(4):369-73. PubMed ID: 16721133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.